This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cigna (CI) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 HMO Stocks Set to Thrive on a Varied Customer Base, Tech Investments
by Debasmita Chatterjee
Rising premiums, technological advancements and increased demand for Medicare plans are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI and CNC are poised to benefit from encouraging industry prospects.
Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Healthcare Stocks Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.
Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
by Zacks Equity Research
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.